Breaking News, Financial News

Financial Report: Curis

Revenues up 23% boosted by Erivedge royalties

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Curis   2Q Revenues: $5.4 million (+23%) 2Q Loss: $1.3 million (loss of $2.9 million 2Q12) YTD Revenues: $6.3 million (earnings were $14.7 million YTD12) YTD Loss: $6.3 million (loss of $660k YTD12) Comments: Revenue growth is related to an increase in royalties from Genentech/Roche’s Erivedge sales in the quarter, up to $805,000, as compared to $253,000 during 2Q12. Curis also received a $550,000 milestone payment from the Leukemia and Lymphoma Society (LLS) related to certain clinica...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters